HFrEF and Worsening HF: Evolving Perspectives on Management is organized by Healio, Vindico Medical Education.
Release Date: August 30, 2023
Expiration Date: August 31, 2024
Activity Description:
Heart failure (HF) affects 64 million people worldwide and is the number 1 cause of hospitalization among patients aged ?65 years. Multiple barriers to improving patient outcomes in HF exist, especially regarding gaps in provider knowledge of guideline-directed medical therapy, recommended pharmacological treatment, and lack of standard protocols. Recent guideline updates for the management of HF include new recommendations for the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and soluble guanylate cyclase (sGC) modulators in select patient populations, as they have both been proven to reduce hospitalizations due to HF. Studies on sGC modulators have also reported other benefits, including prevention, and even reversal, of left ventricular hypertrophy and fibrosis as well as reduction of ventricular afterload through systemic and pulmonary vasodilation. In this CE activity, experts in the field describe the burden of HF and barriers to care, review recent guideline updates and recommendations, and assess the safety and efficacy of sGC modulators in the treatment of HF.
Learning Objective
Upon successful completion of this activity, participants should be better able to:
• Describe the burden of heart failure with reduced ejection fraction (HFrEF) and worsening HF.
• Review the recently updated guideline recommendations and interprofessional strategies for the management of HFrEF and worsening HF.
• Summarize the mechanisms of action of sGC modulators and their safety and efficacy in the treatment of HFrEF.